In a collaborative study published in The Lancet Microbe, the team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and WEHI (Walter and Eliza Hall Institute of Medical Research), revealed MPXV-CRISPR – a powerful diagnostic tool capable of detecting MPXV in clinical samples with acute precision and at a faster rate than any other method, thanks to the power of CRISPR technology.
Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice’s deal in SEA
Ji Xing acquires Biogen’s experimental therapy for acute ischemic stroke: The Shanghai-based biopharma did not disclose the financial terms of the deal. Back in 2018,